Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2

Status

Completed 27Recruiting 9Terminated 6Active not recruiting 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 2Tumor-Agnostic 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Basal Cell 3Recurrence 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Adenocarcinoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × HhAntag691 × Clear all
NCT02956889 2020-01-29

virgilio

Istituto Clinico Humanitas

Phase 2 Terminated
14 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT02067104 2019-08-14

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention

University of Arizona

Phase 2 Terminated
9 enrolled 4 charts
Dermatologic

Carcinoma, Basal Cell

NCT01898598 2017-05-08

A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Terminated
18 enrolled 11 charts
Dermatologic

Carcinoma, Basal Cell

NCT01944943 2017-03-13

VISMOLY

The Lymphoma Academic Research Organisation

Phase 2 Terminated
31 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01880437 2015-12-15

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

Hoffmann-La Roche

Phase 2 Terminated
38 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Myelodysplastic Syndromes

NCT01096732 2014-01-08

HIPPoS

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Terminated
3 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡